SE9301581D0 - Protein formulation - Google Patents

Protein formulation

Info

Publication number
SE9301581D0
SE9301581D0 SE19939301581A SE9301581A SE9301581D0 SE 9301581 D0 SE9301581 D0 SE 9301581D0 SE 19939301581 A SE19939301581 A SE 19939301581A SE 9301581 A SE9301581 A SE 9301581A SE 9301581 D0 SE9301581 D0 SE 9301581D0
Authority
SE
Sweden
Prior art keywords
factor viii
pct
aqueous solution
present
activity
Prior art date
Application number
SE19939301581A
Other languages
English (en)
Inventor
*Oesterberg Thomas
*Fatouros Angelica
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE19939301581A priority Critical patent/SE9301581D0/sv
Publication of SE9301581D0 publication Critical patent/SE9301581D0/sv
Priority to CZ19952869A priority patent/CZ293527B6/cs
Priority to DE69430745T priority patent/DE69430745T2/de
Priority to ES94915307T priority patent/ES2177579T3/es
Priority to PCT/SE1994/000265 priority patent/WO1994026286A1/en
Priority to RU95121755A priority patent/RU2142290C1/ru
Priority to AT94915307T priority patent/ATE218354T1/de
Priority to PT94915307T priority patent/PT700299E/pt
Priority to DK94915307T priority patent/DK0700299T3/da
Priority to AU66597/94A priority patent/AU681883B2/en
Priority to CA002161350A priority patent/CA2161350C/en
Priority to PL94311567A priority patent/PL174866B1/pl
Priority to SK1383-95A priority patent/SK283002B6/sk
Priority to HU9503171A priority patent/HU215263B/hu
Priority to EP94915307A priority patent/EP0700299B1/en
Priority to CN94192021A priority patent/CN1113655C/zh
Priority to KR1019950704933A priority patent/KR100304143B1/ko
Priority to US08/535,251 priority patent/US5962650A/en
Priority to NZ266031A priority patent/NZ266031A/en
Priority to JP52470394A priority patent/JP3751633B2/ja
Priority to ZA942251A priority patent/ZA942251B/xx
Priority to EE9400380A priority patent/EE03118B1/xx
Priority to FI955305A priority patent/FI111910B/sv
Priority to NO19954457A priority patent/NO321769B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
SE19939301581A 1993-05-07 1993-05-07 Protein formulation SE9301581D0 (sv)

Priority Applications (24)

Application Number Priority Date Filing Date Title
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation
JP52470394A JP3751633B2 (ja) 1993-05-07 1994-03-24 因子ｖｉｉｉの酸素低減水溶液
CA002161350A CA2161350C (en) 1993-05-07 1994-03-24 Oxygen-reduced aqueous solution of factor viii
SK1383-95A SK283002B6 (sk) 1993-05-07 1994-03-24 Prípravok s obsahom koagulačného faktora VIII
ES94915307T ES2177579T3 (es) 1993-05-07 1994-03-24 Solucion acuosa de factor viii de bajo contenido en oxigeno.
PCT/SE1994/000265 WO1994026286A1 (en) 1993-05-07 1994-03-24 Oxygen-reduced aqueous solution of factor viii
RU95121755A RU2142290C1 (ru) 1993-05-07 1994-03-24 Водный раствор фактора viii со сниженной концентрацией кислорода
AT94915307T ATE218354T1 (de) 1993-05-07 1994-03-24 Sauerstoff reduzierte wässerige faktor viii- enthaltene lösung
PT94915307T PT700299E (pt) 1993-05-07 1994-03-24 Solucao aquosa de factor viii com teor de oxigenio reduzido
DK94915307T DK0700299T3 (da) 1993-05-07 1994-03-24 Oxygen-reduceret, vandig faktor VIII-opløsning
AU66597/94A AU681883B2 (en) 1993-05-07 1994-03-24 Oxygen-reduced aqueous solution of factor VIII
CZ19952869A CZ293527B6 (cs) 1993-05-07 1994-03-24 Formulace s obsahem koagulačního faktoru VIII a způsob její přípravy
PL94311567A PL174866B1 (pl) 1993-05-07 1994-03-24 Sposób wytwarzania leku zawierającego czynnik krzepnięcia VIII
DE69430745T DE69430745T2 (de) 1993-05-07 1994-03-24 Sauerstoff reduzierte wässerige faktor viii-enthaltene lösung
HU9503171A HU215263B (hu) 1993-05-07 1994-03-24 VIII faktor csökkentett oxigéntartalmú vizes oldata
EP94915307A EP0700299B1 (en) 1993-05-07 1994-03-24 Oxygen-reduced aqueous solution of factor viii
CN94192021A CN1113655C (zh) 1993-05-07 1994-03-24 氧降低的凝固因子vⅲ水溶液
KR1019950704933A KR100304143B1 (ko) 1993-05-07 1994-03-24 산소가감소된인자viii의수용액
US08/535,251 US5962650A (en) 1993-05-07 1994-03-24 Oxygen-reduced aqueous solution of factor VIII
NZ266031A NZ266031A (en) 1993-05-07 1994-03-24 Factor viii composition with reduced dissolved oxygen
ZA942251A ZA942251B (en) 1993-05-07 1994-04-02 Protein formulation.
EE9400380A EE03118B1 (et) 1993-05-07 1994-11-17 Proteiinravim ja selle valmistamismeetod
FI955305A FI111910B (sv) 1993-05-07 1995-11-06 Förfarande för framställning av en läkemedelsformulering innefattande koagulationsfaktor VIII
NO19954457A NO321769B1 (no) 1993-05-07 1995-11-07 Oksygenredusert vandig opplosning av faktor VIII og fremgangsmate for fremstilling av denne.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation

Publications (1)

Publication Number Publication Date
SE9301581D0 true SE9301581D0 (sv) 1993-05-07

Family

ID=20389868

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation

Country Status (24)

Country Link
US (1) US5962650A (sv)
EP (1) EP0700299B1 (sv)
JP (1) JP3751633B2 (sv)
KR (1) KR100304143B1 (sv)
CN (1) CN1113655C (sv)
AT (1) ATE218354T1 (sv)
AU (1) AU681883B2 (sv)
CA (1) CA2161350C (sv)
CZ (1) CZ293527B6 (sv)
DE (1) DE69430745T2 (sv)
DK (1) DK0700299T3 (sv)
EE (1) EE03118B1 (sv)
ES (1) ES2177579T3 (sv)
FI (1) FI111910B (sv)
HU (1) HU215263B (sv)
NO (1) NO321769B1 (sv)
NZ (1) NZ266031A (sv)
PL (1) PL174866B1 (sv)
PT (1) PT700299E (sv)
RU (1) RU2142290C1 (sv)
SE (1) SE9301581D0 (sv)
SK (1) SK283002B6 (sv)
WO (1) WO1994026286A1 (sv)
ZA (1) ZA942251B (sv)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5929031A (en) * 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
MXPA01008515A (es) * 1999-02-22 2003-06-06 Baxter Int Formulaciones novedosas de factor viii libres de albumina.
ES2252028T3 (es) * 1999-07-13 2006-05-16 Biovitrum Ab Composiciones estables del factor viii.
JP3466516B2 (ja) 1999-09-07 2003-11-10 科学技術振興事業団 安定保存可能な酸素輸液剤
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
CN1606452A (zh) * 2001-12-21 2005-04-13 诺沃娜第克公司 修饰的因子ⅶ多肽的液体组合物
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
KR101212025B1 (ko) * 2002-06-21 2013-01-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE454900T1 (de) 2003-05-23 2010-01-15 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
CN102872451A (zh) 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
KR20130026498A (ko) 2003-12-19 2013-03-13 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
PL1750733T3 (pl) 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
ATE471158T1 (de) * 2007-04-17 2010-07-15 Schwabe Willmar Gmbh & Co Verfahren zur herstellung von lagerstabilen lösungen aus pelargonium-extrakten
CN101730707B (zh) * 2007-07-11 2014-12-17 诺沃-诺迪斯克有限公司 使用混合式或多模式树脂来纯化因子ⅷ
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
SI2337580T1 (sl) * 2008-09-03 2012-06-29 Octapharma Ag Stabilizirani sestavki za rekombinanto proizveden faktor VIII
ES2706296T3 (es) 2008-11-07 2019-03-28 Univ Connecticut Formulaciones de Factor VIII
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
KR102210133B1 (ko) 2009-06-09 2021-02-01 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
EP4091645A1 (en) 2010-08-25 2022-11-23 Hemanext Inc. Method for enhancing red blood cell quality and survival during storage
EP4218412A1 (en) 2010-11-05 2023-08-02 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
SG190136A1 (en) 2010-11-05 2013-07-31 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
EP4074395B1 (en) 2011-08-10 2024-01-24 Hemanext Inc. Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device
CA2902061C (en) 2013-02-28 2023-08-08 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
PT3268015T (pt) 2015-03-10 2022-01-06 Hemanext Inc Kits descartáveis de redução de oxigénio, dispositivos e métodos de utilização dos mesmos
EP3285711A4 (en) 2015-04-23 2018-11-07 New Health Sciences, Inc. Anaerobic blood storage containers
CN114748503A (zh) 2015-05-18 2022-07-15 希玛奈克斯特股份有限公司 储存全血的方法及其组合物
AU2017271545C1 (en) 2016-05-27 2023-06-15 Hemanext Inc. Anaerobic blood storage and pathogen inactivation method
CN112601545A (zh) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 工艺和疫苗

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2896381A (en) * 1954-05-27 1959-07-28 Hodes Lange Corp Method and apparatus for treating and filling ampoules
US3143471A (en) * 1962-01-18 1964-08-04 Merck & Co Inc Argon method of drying and preserving lyophilized therapeutic products
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
EP0212040B1 (de) * 1985-08-05 1990-05-23 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren
US4709819A (en) * 1986-07-23 1987-12-01 Environmental Diagnostics, Inc. Method for preserving plated media and product
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
KR100468551B1 (ko) * 1994-10-31 2005-03-16 킴벌리-클라크 월드와이드, 인크. 고밀도부직필터매체

Also Published As

Publication number Publication date
EE03118B1 (et) 1998-10-15
WO1994026286A1 (en) 1994-11-24
CZ293527B6 (cs) 2004-05-12
HU9503171D0 (en) 1996-01-29
EP0700299A1 (en) 1996-03-13
KR100304143B1 (ko) 2001-11-22
NO321769B1 (no) 2006-07-03
CA2161350C (en) 2007-10-30
JP3751633B2 (ja) 2006-03-01
CN1113655C (zh) 2003-07-09
HU215263B (hu) 1998-11-30
EP0700299B1 (en) 2002-06-05
AU6659794A (en) 1994-12-12
US5962650A (en) 1999-10-05
NO954457D0 (no) 1995-11-07
JPH08509745A (ja) 1996-10-15
NO954457L (no) 1995-11-07
PL311567A1 (en) 1996-02-19
ZA942251B (en) 1994-11-01
DE69430745D1 (de) 2002-07-11
CA2161350A1 (en) 1994-11-24
HUT73693A (en) 1996-09-30
FI111910B (sv) 2003-10-15
DE69430745T2 (de) 2002-10-17
FI955305A0 (sv) 1995-11-06
RU2142290C1 (ru) 1999-12-10
FI955305A (sv) 1995-11-06
NZ266031A (en) 1997-04-24
KR960702317A (ko) 1996-04-27
AU681883B2 (en) 1997-09-11
PT700299E (pt) 2002-11-29
PL174866B1 (pl) 1998-09-30
SK283002B6 (sk) 2003-01-09
ES2177579T3 (es) 2002-12-16
ATE218354T1 (de) 2002-06-15
DK0700299T3 (da) 2002-09-23
SK138395A3 (en) 1997-02-05
CN1122573A (zh) 1996-05-15
CZ286995A3 (en) 1996-05-15

Similar Documents

Publication Publication Date Title
SE9301581D0 (sv) Protein formulation
BR9607922A (pt) Produto medicamentoso final de uma proteína de plasma processos para preparar o produto medicamentoso final para melhorar a estabilidade de longo prazo de uma proteína de plasma e para tratar hemofilia e uso de um produto medicamentoso final
CA1158551A (en) Plasminogen preparations
ATE73671T1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
EE9700218A (et) Trombiini inhibiitorit sisaldav säilituskindel vesilahus süstimiseks
SE9402119D0 (sv) Solution
ATE66147T1 (de) Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
GR3036277T3 (en) Methods for preventing degradation of protein C.
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี